Since glutamine supplementation in H. bilis infected cells was also able to decrease activation of the NF-κB, AP-1 and CREB pathways as well as lower IL-8 production in the colon cancer cells used in our study, glutamine administration could be considered as a protective therapeutic approach against H. bilis induced IBD and colitis. The gene discussed is NFKB1; the disease is inflammatory bowel disease.